BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 9578421)

  • 1. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
    Lethé B; van der Bruggen P; Brasseur F; Boon T
    Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
    Zakut R; Topalian SL; Kawakami Y; Mancini M; Eliyahu S; Rosenberg SA
    Cancer Res; 1993 Jan; 53(1):5-8. PubMed ID: 8416750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
    van der Bruggen P; Szikora JP; Boël P; Wildmann C; Somville M; Sensi M; Boon T
    Eur J Immunol; 1994 Sep; 24(9):2134-40. PubMed ID: 7522162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
    J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
    Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
    J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
    Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma.
    Yamashita N; Ishibashi H; Hayashida K; Kudo J; Takenaka K; Itoh K; Niho Y
    Hepatology; 1996 Dec; 24(6):1437-40. PubMed ID: 8938177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
    Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
    Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
    So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
    Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.
    Gibbs P; Hutchins AM; Dorian KT; Vaughan HA; Davis ID; Silvapulle M; Cebon JS
    Melanoma Res; 2000 Jun; 10(3):259-64. PubMed ID: 10890380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
    Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
    Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Bao L; Dunham K; Lucas K
    Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
    Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
    Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.